US Bancorp DE Lowers Stock Position in Avantor, Inc. (NYSE:AVTR)

US Bancorp DE reduced its holdings in Avantor, Inc. (NYSE:AVTR) by 52.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,002 shares of the company’s stock after selling 6,613 shares during the period. US Bancorp DE’s holdings in Avantor were worth $126,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB increased its position in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after acquiring an additional 625 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after acquiring an additional 1,067 shares during the period. UMB Bank n.a. increased its holdings in shares of Avantor by 56.3% in the 4th quarter. UMB Bank n.a. now owns 2,981 shares of the company’s stock valued at $63,000 after acquiring an additional 1,074 shares during the period. CKW Financial Group increased its stake in Avantor by 116.7% in the 4th quarter. CKW Financial Group now owns 5,200 shares of the company’s stock valued at $110,000 after buying an additional 2,800 shares during the period. Finally, First Horizon Advisors Inc. increased its stake in Avantor by 30.8% in the 3rd quarter. First Horizon Advisors Inc. now owns 5,629 shares of the company’s stock valued at $146,000 after buying an additional 1,326 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Stock Up 3.3 %

Shares of NYSE:AVTR opened at $16.34 on Monday. The firm has a market cap of $11.12 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 1.55 and a beta of 1.30. The company has a fifty day simple moving average of $19.51 and a 200 day simple moving average of $22.01. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. Avantor, Inc. has a 12-month low of $15.37 and a 12-month high of $28.00.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter in the prior year, the business earned $0.22 earnings per share. On average, equities research analysts anticipate that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Insider Activity at Avantor

In other Avantor news, EVP James Bramwell sold 3,758 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $65,877.74. Following the sale, the executive vice president now directly owns 87,379 shares in the company, valued at approximately $1,531,753.87. The trade was a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Steven W. Eck sold 4,907 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total transaction of $86,019.71. Following the completion of the sale, the chief accounting officer now owns 40,604 shares in the company, valued at approximately $711,788.12. This trade represents a 10.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AVTR shares. Morgan Stanley lowered their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Citigroup decreased their price target on shares of Avantor from $22.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. UBS Group reissued a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Raymond James reissued an “outperform” rating and issued a $24.00 target price (down from $26.00) on shares of Avantor in a research report on Monday, February 10th. Finally, Wells Fargo & Company cut their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Avantor presently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.